PN,31701
SC,0001
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F317A1729464449
OL,3,CClinical trial offers new hope to
OL,4,Cwomen with ovarian cancer
OL,6,FExperts are so excited by the latest
OL,7,Ffindings that they hope the treatment
OL,8,Fwill change practice globally for this
OL,9,Ftype of cancer, as ITV News Reporter
OL,10,FOlivia Guthrie reports
OL,12,FWomen with a type of ovarian cancer
OL,13,Fthat is very difficult to treat have
OL,14,Fshown remarkable results in a clinical
OL,15,Ftrial testing a new combination of
OL,16,Fdrugs.
OL,1,W~k4~sj5j5~s1G                    G1/7
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,318,300,200,140,000,100
PN,31702
SC,0002
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F317A1729464449
OL,3,CClinical trial offers new hope to
OL,4,Cwomen with ovarian cancer
OL,6,FAlmost a third (31%) of women with low-
OL,7,Fgrade serous ovarian cancer, which
OL,8,Fdoes not respond well to chemotherapy,
OL,9,Fsaw their tumours shrink or stop
OL,10,Fgrowing when taking a combination of
OL,11,Favutometinib and defactinib.
OL,13,FThe results in patients who had a
OL,14,Fmutation in a gene called KRAS were
OL,15,Feven more promising, with 44% of
OL,16,Fpatients seeing their tumour shrink.
OL,1,W~k4~sj5j5~s1G                    G2/7
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,318,300,200,140,000,100
PN,31703
SC,0003
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F317A1729464449
OL,3,CClinical trial offers new hope to
OL,4,Cwomen with ovarian cancer
OL,6,FExperts are so excited by the latest
OL,7,Ffindings that they hope the treatment
OL,8,Fwill change practice globally for this
OL,9,Ftype of cancer, and offer hope to
OL,10,Fwomen with no or few treatment options.
OL,12,FThe clinical trial on the drugs is
OL,13,Fbeing led by Professor Susana
OL,14,FBanerjee, consultant medical
OL,15,Foncologist at the Royal Marsden NHS
OL,16,FFoundation Trust and from the
OL,17,FInstitute of Cancer Research, London.
OL,19,FShe said: "These are significant
OL,20,Fresults from the second phase of this
OL,21,Ftrial.
OL,26,@{D@KOU
OL,1,W~k4~sj5j5~s1G                    G3/7
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,318,300,200,140,000,100
PN,31704
SC,0004
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F317A1729464449
OL,3,CClinical trial offers new hope to
OL,4,Cwomen with ovarian cancer
OL,6,F"The toxicities for patients are much
OL,7,Flower, which means side effects are
OL,8,Ffewer than with some conventional
OL,9,Ftreatments.
OL,11,F"The combination of avutometinib and
OL,12,Fdefactinib promises a new standard of
OL,13,Fcare for people with recurrent low-
OL,14,Fgrade serous ovarian cancer.
OL,16,F"We're now looking to recruit patients
OL,17,Ffor our phase three trial and hope
OL,18,Fresults will continue to show better
OL,19,Foutcomes for patients."
OL,26,@nD@AOUsD@AOUxD@AOU{D@WO]
OL,1,W~k4~sj5j5~s1G                    G4/7
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,318,300,200,140,000,100
PN,31705
SC,0005
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F317A1729464449
OL,3,CClinical trial offers new hope to
OL,4,Cwomen with ovarian cancer
OL,6,FThe drugs being used in the trial are
OL,7,Finvestigational and are being
OL,8,Fdeveloped by biotech company Verastem
OL,9,FOncology.
OL,11,FThe new Ramp 201 study results were
OL,12,Fpresented on Thursday at the
OL,13,FInternational Gynaecologic Cancer
OL,14,FSociety's meeting in Dublin.
OL,16,FThey showed that in 115 people with
OL,17,Flow-grade serous ovarian cancer, 31%
OL,18,Fsaw their tumours shrink or stop
OL,19,Fgrowing on the drugs, compared to 10%
OL,20,For under response rate to chemotherapy
OL,21,For hormone therapies.
OL,1,W~k4~sj5j5~s1G                    G5/7
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,318,300,200,140,000,100
PN,31706
SC,0006
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F317A1729464449
OL,3,CClinical trial offers new hope to
OL,4,Cwomen with ovarian cancer
OL,6,FLow grade serous ovarian cancer is a
OL,7,Frare subtype of ovarian cancer, which
OL,8,Fis more likely to affect younger women
OL,9,Fand is more resistant to chemotherapy
OL,10,Fthan other types.
OL,12,FMany people are diagnosed when the
OL,13,Fcancer has spread, and more than 70%
OL,14,Fsee their cancer come back even after
OL,15,Fstandard treatment.
OL,17,FBoth avutometinib and defactinib work
OL,18,Fby blocking signals that encourage
OL,19,Fcancer cells to grow.
OL,1,W~k4~sj5j5~s1G                    G6/7
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,318,300,200,140,000,100
PN,31707
SC,0007
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F317A1729464449
OL,3,CClinical trial offers new hope to
OL,4,Cwomen with ovarian cancer
OL,6,FIn the trial, only 10% of patients
OL,7,Fquit, meaning most could tolerate the
OL,8,Fdrugs and any side-effects.
OL,1,W~k4~sj5j5~s1G                    G7/7
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,318,300,200,140,000,100
